|
|
Blood, 1 February 2006, Vol. 107, No. 3, pp. 1166-1173.
Prepublished online as a Blood First Edition Paper on October 18, 2005; DOI 10.1182/blood-2005-06-2325.
 Previous Article | Next Article 
Submitted June 10, 2005
Accepted September 27, 2005
AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML
Daniel J Pearce, David Taussig, Kazem Zibara, Lan-Lan Smith, Christopher M Ridler, Claude Preudhomme, Bryan D Young, Ama Z Rohatiner, T A Lister, and Dominique Bonnet*
Hematopoietic Stem Cell Laboratory, London Research Institute, Cancer Research UK, London, United Kingdom
Hematopoietic Stem Cell Laboratory, London Research Institute, Cancer Research UK, London, United Kingdom; Cancer Research UK Medical Oncology Unit, St. Bartholomew's Hospital, London, United Kingdom
Hematopoietic Stem Cell Laboratory, London Research Institute, Cancer Research UK, London, United Kingdom; Medical Oncology Laboratory, Cancer Research UK, Queen Mary & St Bartholomew's Medical School, London, United Kingdom
Laboratoire d'hematologie A, Hopital Calmette, Lille, France
Medical Oncology Laboratory, Cancer Research UK, Queen Mary & St Bartholomew's Medical School, London, United Kingdom
Cancer Research UK Medical Oncology Unit, St. Bartholomew's Hospital, London, United Kingdom
* Corresponding author; email: dominique.bonnet{at}cacner.org.uk.
The non-obese diabetic/severe combined immunodeficient (NOD/SCID) assay is the current model for assessment of human normal and leukemic stem cells. We explored why 51% of 59 acute myeloid leukemia (AML) patients were unable to initiate leukemia in NOD/SCID mice. Increasing the cell dose, using more permissive recipients and alternative tissue sources, did not cause AML engraftment in most previously non-engrafting AML samples. Homing of AML cells to the marrow was the same between engrafters and non-engrafters. FLT-3 ITD and nucleophosmin mutations occurred at a similar frequency in engrafters and non-engrafters. The only variable that was related to engraftment ability was the karyotypically-defined risk stratification of individual AML cases. Interestingly, follow-up of younger patients with intermediate-risk AML revealed a significant difference in overall survival between NOD/SCID-engrafting and non-engrafting AMLs. Hence, the ability of AML to engraft in the NOD/SCID assay seems to be an inherent property of AML cells, independent of homing, conditioning or cell frequency/source, which is directly related to prognosis. Our results suggest an important difference between leukemic initiating cells between engrafting and non-engrafting AML cases that correlates with treatment response.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J.M Adams, P.N. Kelly, A. Dakic, S. Carotta, S.L. Nutt, and A. Strasser
Role of "Cancer Stem Cells" and Cell Survival in Tumor Development and Maintenance
Cold Spring Harb Symp Quant Biol,
November 6, 2008;
(2008)
sqb.2008.73.004v1.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. C. Taussig, F. Miraki-Moud, F. Anjos-Afonso, D. J. Pearce, K. Allen, C. Ridler, D. Lillington, H. Oakervee, J. Cavenagh, S. G. Agrawal, et al.
Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells
Blood,
August 1, 2008;
112(3):
568 - 575.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Adams and A. Strasser
Is Tumor Growth Sustained by Rare Cancer Stem Cells or Dominant Clones?
Cancer Res.,
June 1, 2008;
68(11):
4018 - 4021.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Adams, P. N. Kelly, A. Dakic, S. L. Nutt, and A. Strasser
Response to Comment on "Tumor Growth Need Not Be Driven by Rare Cancer Stem Cells"
Science,
December 14, 2007;
318(5857):
1722d - 1722d.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Schepers, D. van Gosliga, A. T. J. Wierenga, B. J. L. Eggen, J. J. Schuringa, and E. Vellenga
STAT5 is required for long-term maintenance of normal and leukemic human stem/progenitor cells
Blood,
October 15, 2007;
110(8):
2880 - 2888.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. van Rhenen, G. A. M. S. van Dongen, A. Kelder, E. J. Rombouts, N. Feller, B. Moshaver, M. S.-v. Walsum, S. Zweegman, G. J. Ossenkoppele, and G. Jan Schuurhuis
The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells
Blood,
October 1, 2007;
110(7):
2659 - 2666.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Spoo, M. Lubbert, W. G. Wierda, and J. A. Burger
CXCR4 is a prognostic marker in acute myelogenous leukemia
Blood,
January 15, 2007;
109(2):
786 - 791.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Testa and R. Riccioni
Deregulation of apoptosis in acute myeloid leukemia
Haematologica,
January 1, 2007;
92(1):
81 - 94.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Grimwade
NPM1 mutation in AML: WHO and why?
Blood,
December 15, 2006;
108(13):
3965 - 3965.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kalinkovich, S. Tavor, A. Avigdor, J. Kahn, A. Brill, I. Petit, P. Goichberg, M. Tesio, N. Netzer, E. Naparstek, et al.
Functional CXCR4-Expressing Microparticles and SDF-1 Correlate with Circulating Acute Myelogenous Leukemia Cells.
Cancer Res.,
November 15, 2006;
66(22):
11013 - 11020.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
